Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7115)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 6, 2021 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tian C, Li N, Bai Y, Xiao H, Li S, Ge QG, Shen N, Ma QB. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. World J Clin Cases 2021; 9(1): 47-60 [PMID: 33511171 DOI: 10.12998/wjcc.v9.i1.47] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i1/47.htm |
| Number | Citing Articles |
| 1 |
Ye Liu, Ran Lu, Junhong Wang, Qin Cheng, Ruitao Zhang, Shuisheng Zhang, Yunyi Le, Haining Wang, Wenhua Xiao, Hongwei Gao, Lin Zeng, Tianpei Hong. Diabetes, even newly defined by HbA1c testing, is associated with an increased risk of in-hospital death in adults with COVID-19. BMC Endocrine Disorders 2021; 21(1) doi: 10.1186/s12902-021-00717-6
|
| 2 |
Farnoosh Nozari, Nasrin Hamidizadeh, Salvatore Corrao. The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review. International Journal of Hypertension 2022; 2022: 1 doi: 10.1155/2022/5937802
|
| 3 |
Safaet Alam, Taslima Binte Kamal, Md. Moklesur Rahman Sarker, Jin-Rong Zhou, S. M. Abdur Rahman, Isa Naina Mohamed. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.659577
|